IRIDEX Reports $12.6 Million Revenue, 7.4% Decline in Latest Quarter

IRIDEX Corporation reported a total revenue of $12.6 million for the three months ended July 4, 2026, a decrease of 7.4% compared to $13.6 million in the same period last year. For the six months, revenue also fell by 4.3% to $24.4 million from $25.5 million. The decline was attributed primarily to decreased sales in the retina product line, which saw a drop of 19.4% in the latest quarter. In contrast, the glaucoma product line, particularly the Cyclo G6 laser system, experienced a 19% increase in revenue, reflecting a shift in customer demand.

The company's gross profit for the second quarter was $4.3 million, down from $4.7 million a year earlier, resulting in a gross margin of 34.2%, slightly lower than the previous year's 34.5%. The decrease in gross margin was linked to rising manufacturing costs and tariffs affecting product costs. Operating expenses totaled $5.3 million, a reduction from $5.6 million in the prior year, driven by lower general and administrative costs due to cost-saving initiatives. Despite these reductions, IRIDEX reported a net loss of $1.3 million for the quarter, compared to a loss of $994,000 in the same period last year.

In terms of operational metrics, the company maintained a steady employee headcount while focusing on cost management across its research and development, sales, and marketing departments. The total cash and cash equivalents as of July 4, 2026, stood at $4.7 million, down from $6.0 million at the beginning of the year. The company’s working capital also decreased to $10.8 million from $12.0 million, reflecting the ongoing challenges in the capital expenditure landscape due to macroeconomic uncertainties.

Strategically, IRIDEX continues to leverage its partnership with Topcon Corporation, which remains a significant contributor to its revenue, accounting for approximately 33% of total sales in the latest quarter. The company is also focused on expanding its product offerings and enhancing its market presence, particularly in the glaucoma treatment segment. Looking ahead, IRIDEX anticipates that ongoing geopolitical tensions and economic conditions may continue to impact customer purchasing decisions, but it remains committed to its growth strategy and believes its existing cash reserves will support operations for the next 12 months.

Overall, while IRIDEX faces challenges in revenue generation and profitability, it is actively managing costs and leveraging strategic partnerships to navigate the current market landscape. The company’s focus on innovation and product development, particularly in the glaucoma treatment space, positions it for potential recovery as market conditions improve.